Since HIV targets cells that express CD4, especially CD4+-T cells, and decreased IFNγ production in the context of HIV infection occurs in cells of the acquired immune system [45], [47] the finding of inherent capacity for IFNγ production among innate cells could be exploited to therapeutic advantage. The gene discussed is IFNG; the disease is HIV infectious disease.